Article Details
Retrieved on: 2018-03-10 03:59:54
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>For Ken Mulvany, it's what we should know, based on what we already know, that's particularly interesting. He established BenevolentAI to take the notoriously challenging task of developing new drugs beyond the limitations of human intelligence and into the world of <b>artificial intelligence</b> (AI). It's now ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here